Tissue-level inflammation and ventricular remodeling in hypertrophic cardiomyopathy Richard C. BeckerA. Phillip Owens IIISakthivel Sadayappan ReviewPaper 02 January 2020 Pages: 177 - 183
The dawn of aspirin free strategy after short term dual antiplatelet for percutaneous coronary intervention: meta-analysis of randomized controlled trials Mohammed OsmanPeter D. FarjoSudarshan Balla ReviewPaper 21 November 2019 Pages: 184 - 191
Rationale and design of “Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)” study Ying X. GueRahim KanjiDiana A. Gorog OriginalPaper Open access 23 December 2019 Pages: 192 - 198
Resolution of acute lower extremity deep vein thrombosis with rivaroxaban compared to warfarin Damon E. HoughtonAlexander LekahWaldemar E. Wysokinski OriginalPaper 17 August 2019 Pages: 199 - 205
Intravenous unfractionated heparin dosing in obese patients using anti-Xa levels Alex M. EbiedTammy LiYiqing Chen OriginalPaper 05 September 2019 Pages: 206 - 213
Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial Walter AgenoRenato D. LopesAlexander T. Cohen OriginalPaper 06 September 2019 Pages: 214 - 219
Incidence of residual perfusion defects by lung scintigraphy in patients treated with rivaroxaban compared with warfarin for acute pulmonary embolism Ming Sheng LimDee NandurkarSanjeev Chunilal OriginalPaper 06 September 2019 Pages: 220 - 227
Induction of tissue factor expression by anti-β2-glycoprotein I is mediated by tumor necrosis factor α Anne HollerbachNadine Müller-CallejaKarl J. Lackner OriginalPaper 15 October 2019 Pages: 228 - 234
Change in matrix metalloproteinase 2, 3, and 9 levels at the time of and after acute atherothrombotic myocardial infarction Ugochukwu Shola OwolabiAlok Ravindra AmraotkarAndrew Paul DeFilippis OriginalPaper 05 December 2019 Pages: 235 - 244
Determination of the cut-off prothrombin time to estimate plasma rivaroxaban overdose status Bohyun KimSeongsoo JangChan-Jeoung Park OriginalPaper 10 September 2019 Pages: 245 - 250
Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study Maria Cristina VedovatiMaria Giulia MosconiCecilia Becattini OriginalPaper 13 September 2019 Pages: 251 - 258
Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients Jacob T. BeyerStuart E. LindTyree H. Kiser OriginalPaper 26 September 2019 Pages: 259 - 267
High incidence of under-treated atrial fibrillation: perspectives from an Asian Stroke Endovascular Thrombectomy Registry Benjamin Yong-Qiang TanAloysius Sheng-Ting LeowLeonard Leong-Litt Yeo Letter to the Editor 13 December 2019 Pages: 268 - 270
Direct oral anticoagulants: a review on the current role and scope of reversal agents Rahul ChaudharyTushar SharmaPaul Gurbel ReviewPaper 11 September 2019 Pages: 271 - 286
Low persistence to rivaroxaban or warfarin among patients with new venous thromboembolism at a safety net academic medical center Sweta Meet PatelTina WangMikhail Akbashev OriginalPaper 09 October 2019 Pages: 287 - 293
Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care Markus GulilatDenise KellerUte I. Schwarz OriginalPaper 28 September 2019 Pages: 294 - 303
Factors associated with women’s adherence to postpartum thromboprophylaxis Amihai RottenstreichAdi KarlinMisgav Rottenstreich OriginalPaper 06 September 2019 Pages: 304 - 311
Congenital fibrinogen disorders with repeated thrombosis Xiuli ZhangChuang ZhangXueli Guo OriginalPaper 21 September 2019 Pages: 312 - 315
Does telehealth improve anticoagulation management in patient service centers (PSC)? A pilot project Maria R. BernsteinLibiny JohnAlex C. Spyropoulos BriefCommunication 02 January 2020 Pages: 316 - 320
Antithrombotic therapy for chronic coronary syndrome and atrial fibrillation: less might be more Bernhard WernlyDeepak L. BhattChristian Jung BriefCommunication 03 December 2019 Pages: 321 - 324
The role of anticoagulation in pylephlebitis: a retrospective examination of characteristics and outcomes Leonard NaymagonDouglas TremblayJohn Mascarenhas OriginalPaper 06 September 2019 Pages: 325 - 331
Initiation of a fixed- dose four- factor prothrombin complex concentrate protocol Ajay Kumar MishraKamal Kant SahuSusan V. George Letter to the Editor 16 December 2019 Pages: 332 - 333
A case report of severe bleeding due to lupus anticoagulant hypoprothrombinemia syndrome Elsa MeirelesFilipe MachadoAna Spínola Report 12 September 2019 Pages: 334 - 336